Literature DB >> 6099738

Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertension.

C I Johnston, B J Jackson, I Larmour, R Cubella, D Casley.   

Abstract

Enalapril lowers blood pressure both acutely and during long-term therapy in patients with essential hypertension. After a single 10 mg dose of enalapril a close relationship between plasma enalaprilic acid (MK-422) levels, angiotensin converting enzyme (ACE) inhibition and the acute hypotensive and hormonal effects was demonstrated. During long-term administration of enalapril, a similar relationship between the plasma enalaprilic acid level, ACE inhibition and the hypotensive effect was shown, although the dose-response curve for plasma enalaprilic acid to ACE inhibition was displaced to the right compared to the acute dose-response curve. Several weeks' administration of enalapril was needed to reach stable plateau levels of plasma enalaprilic acid and ACE inhibition. During long-term treatment with enalapril in essential hypertension, there was sustained inhibition of ACE and the associated hormonal changes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6099738      PMCID: PMC1463475          DOI: 10.1111/j.1365-2125.1984.tb02602.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  27 in total

1.  Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients.

Authors:  D B Case; S A Atlas; J H Laragh; J E Sealey; P A Sullivan; D N McKinstry
Journal:  Prog Cardiovasc Dis       Date:  1978 Nov-Dec       Impact factor: 8.194

2.  Captopril compared with other antirenin system agents in hypertensive patients: its triphasic effects on blood pressure and its use to identify and treat the renin factor.

Authors:  J H Laragh; D B Case; S A Atlas; J E Sealey
Journal:  Hypertension       Date:  1980 Jul-Aug       Impact factor: 10.190

3.  Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421".

Authors:  H Gavras; J Biollaz; B Waeber; H R Brunner; I Gavras; R O Davies
Journal:  Lancet       Date:  1981-09-12       Impact factor: 79.321

4.  Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I.

Authors:  J Biollaz; M Burnier; G A Turini; D B Brunner; M Porchet; H J Gomez; K H Jones; F Ferber; W B Abrams; H Gavras; H R Brunner
Journal:  Clin Pharmacol Ther       Date:  1981-05       Impact factor: 6.875

5.  A new class of angiotensin-converting enzyme inhibitors.

Authors:  A A Patchett; E Harris; E W Tristram; M J Wyvratt; M T Wu; D Taub; E R Peterson; T J Ikeler; J ten Broeke; L G Payne; D L Ondeyka; E D Thorsett; W J Greenlee; N S Lohr; R D Hoffsommer; H Joshua; W V Ruyle; J W Rothrock; S D Aster; A L Maycock; F M Robinson; R Hirschmann; C S Sweet; E H Ulm; D M Gross; T C Vassil; C A Stone
Journal:  Nature       Date:  1980-11-20       Impact factor: 49.962

6.  Clinical use of an orally acting converting enzyme inhibitor: captopril.

Authors:  H R Brunner; H Gavras; B Waeber; S C Textor; G A Turini; J P Wauters
Journal:  Hypertension       Date:  1980 Jul-Aug       Impact factor: 10.190

7.  Long-term effects of captopril (SQ14 225) on blood-pressure and hormone levels in essential hypertension.

Authors:  C I Johnston; J A Millar; B P McGrath; P G Matthews
Journal:  Lancet       Date:  1979-09-08       Impact factor: 79.321

8.  Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents.

Authors:  M A Ondetti; B Rubin; D W Cushman
Journal:  Science       Date:  1977-04-22       Impact factor: 47.728

Review 9.  Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

10.  Acute effects of captopril on blood pressure and circulating hormone levels in salt-replete and depleted normal subjects and essential hypertensive patients.

Authors:  J A Millar; B P McGrath; P G Matthews; C I Johnston
Journal:  Clin Sci (Lond)       Date:  1981-07       Impact factor: 6.124

View more
  12 in total

Review 1.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

2.  Lisinopril in hypertensive patients with and without renal failure.

Authors:  B A van Schaik; G G Geyskes; P Boer
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 3.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

4.  Evaluation of the safety of enalapril in the treatment of heart failure in the very old.

Authors:  C J O'Neill; S G Bowes; C M Sullens; J P Royston; W B Hunt; M J Denham; R J Dobbs; S M Dobbs
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 5.  Systemic and coronary haemodynamics and pharmacodynamics of enalapril and enalaprilat in congestive heart failure.

Authors:  K Chatterjee; T De Marco
Journal:  Drugs       Date:  1990       Impact factor: 9.546

6.  The pharmacokinetics of enalapril in patients with compensated liver cirrhosis.

Authors:  T Baba; S Murabayashi; T Tomiyama; K Takebe
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

Review 7.  An overview of the clinical pharmacology of enalapril.

Authors:  R O Davies; H J Gomez; J D Irvin; J F Walker
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

8.  Clinically Relevant Doses of Enalapril Mitigate Multiple Organ Radiation Injury.

Authors:  Eric P Cohen; Brian L Fish; John E Moulder
Journal:  Radiat Res       Date:  2016-03-02       Impact factor: 2.841

Review 9.  Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. An overview.

Authors:  R J MacFadyen; P A Meredith; H L Elliott
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

Review 10.  Choosing the right ACE inhibitor. A guide to selection.

Authors:  G Leonetti; C Cuspidi
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.